SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 — Senti Biosciences announced the completion of patient enrollment in its Phase 1 clinical trial evaluating SENTI-202, a first-in-class logic-gated CAR-NK cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML), marking a significant clinical development milestone as the company prepares for pivotal study planning and regulatory engagement with the U.S. Food and Drug Administration.

Science Significance

The enrollment milestone advances one of the most technologically sophisticated programs in next-generation immuno-oncology. SENTI-202 is engineered using synthetic biology “Gene Circuit” technology, enabling programmable immune responses designed to selectively target malignant cells while sparing healthy tissue. The therapy integrates an OR-gate activating CAR targeting CD33 and FLT3 leukemia antigens, a NOT-gate inhibitory CAR recognizing EMCN on healthy stem cells, and calibrated IL-15 cytokine release to enhance persistence and anti-tumor activity. Clinical data presented at a major hematology congress demonstrated deep measurable residual disease (MRD)-negative durable complete remissions alongside a favorable safety profile in heavily pretreated AML patients. This logic-gated architecture represents a scientific evolution beyond conventional CAR constructs, introducing multi-antigen targeting and built-in safety control mechanisms.

Regulatory Significance

Regulatory momentum surrounding SENTI-202 is notable. The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, a pathway designed to expedite development and review for transformative regenerative medicines. It has also secured Orphan Drug Designation for hematologic malignancies, reinforcing its rare disease development pathway. With Phase 1 enrollment completed, the company plans regulatory discussions in 2026 to align on pivotal registration trial design, dose expansion strategy, and potential accelerated approval routes. Such designations strengthen clinical development efficiency by enabling intensified FDA interaction, rolling data review, and pathway optimization.

Business Significance

Completion of enrollment represents a major value-inflection point for Senti Biosciences’ cell therapy portfolio. SENTI-202 is being developed as an off-the-shelf allogeneic NK cell therapy, manufactured from healthy donors, cryopreserved, and distributed for on-demand clinical use—offering scalability advantages over autologous CAR-T approaches. The milestone supports transition into late-stage development planning, enhancing partnership potential, licensing discussions, and investor confidence. The company is also evaluating indication expansion into newly diagnosed AML and pediatric AML, broadening commercial opportunity while leveraging its proprietary Gene Circuit platform across additional oncology targets.

Patients’ Significance

For patients with relapsed or refractory AML, therapeutic innovation is urgently needed. The disease remains one of the most aggressive hematologic malignancies, with poor survival outcomes following treatment relapse. SENTI-202’s dual-antigen targeting strategy aims to eliminate both leukemic blasts and stem cell reservoirs while minimizing bone marrow toxicity. Early MRD-negative remission signals suggest potential for deeper disease clearance and improved long-term outcomes. Additionally, the off-the-shelf design may reduce manufacturing wait times, enabling faster treatment access for critically ill patients.

Policy Significance

The program highlights broader healthcare policy momentum supporting advanced cell and gene therapies. Regulatory initiatives such as RMAT and Orphan Drug frameworks are designed to accelerate innovation for life-threatening diseases lacking adequate treatment options. As engineered immune therapies evolve, policymakers and regulators continue shaping guidance around GMP manufacturing, potency assays, supply chain traceability, and long-term safety monitoring. SENTI-202’s development pathway reflects how synthetic biology and regenerative medicine platforms are reshaping regulatory science and therapeutic innovation policy landscapes.

With Phase 1 enrollment complete and pivotal planning underway, SENTI-202 advances as a next-generation immunotherapy candidate integrating programmable biology, dual-target tumor recognition, and safety-gated immune activation. The milestone reinforces Senti Biosciences’ position at the forefront of engineered cell therapy innovation while bringing new therapeutic hope to patients facing the most treatment-resistant forms of acute myeloid leukemia.

Source: Senti Biosciences press release